RSV is the leading cause of hospitalization in US infants, and in August 2023, the CDC’s vaccine advisory group recommended ...

The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

Officials estimated that 228 fewer babies younger than 3 months older were hospitalized for serious RSV infection during the peak of the season, a number they hope will increase as more women are ...

HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that everyone in the U.S. ages 6 months and older receive a flu shot for the ...

BEYFORTUS administration can be timed to coincide with the RSV season. BEYFORTUS has been approved for use in the US, the European Union, China, Japan, and many other countries around the world.

The largest US real-world study of BEYFORTUS (nirsevimab-alip) 50mg and 100mg Injection successfully met both of its co-primary endpoints, demonstrating that BEYFORTUS provides protection for babies ...

BEYFORTUS is a long-acting monoclonal antibody approved for the prevention of RSV lower respiratory tract disease (LRTD) in newborns and infants born during or entering their first RSV season, and ...

The Beyfortus® distribution agreement builds upon Dr. Reddy's successful vaccine partnership with Sanofi established in 2024 as part of its strategy of“expanding innovation and building for ...

Sanofi (ENXTPA:SAN) has recently announced it will begin shipping Beyfortus in early Q3 2025. This move aims to support healthcare providers ahead of the RSV season. Sanofi's commitment to increasing ...